Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric S Fischer

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Nature Communications|May 8, 2026
CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trialsWallace Bourgeois, Hannah E Rice, Daniela V Wenge, et al.
Journal of the American Chemical Society|June 26, 2026
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II InhibitionJi Hyeon Kim, Caitlin E Mills, Zuzanna Kozicka, et al.
Cell Chemical Biology|February 11, 2026
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesisPeter Geon Kim, Christopher B Hergott, Aidan P Miller, et al.
Nature|June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin KMikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Cancer Discovery|September 21, 2021
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase InhibitorsQing Li, Baishan Jiang, Jiaye Guo, et al.
Blood|December 14, 2023
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AMLWallace Bourgeois, Jevon A Cutler, Brandon J Aubrey, et al.
Nature Cancer|May 9, 2022
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemiaBrandon J Aubrey, Jevon A Cutler, Wallace Bourgeois, et al.
Nature Communications|June 30, 2022
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational statePeter G Miller, Murugappan Sathappa, Jamie A Moroco, et al.
Science Advances|February 6, 2021
Targeting oncoproteins with a positive selection assay for protein degradersVidyasagar Koduri, Leslie Duplaquet, Benjamin L Lampson, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Nature Communications|May 8, 2026
CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trialsWallace Bourgeois, Hannah E Rice, Daniela V Wenge, et al.
Journal of the American Chemical Society|June 26, 2026
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II InhibitionJi Hyeon Kim, Caitlin E Mills, Zuzanna Kozicka, et al.
Cell Chemical Biology|February 11, 2026
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesisPeter Geon Kim, Christopher B Hergott, Aidan P Miller, et al.
Nature|June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin KMikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Cancer Discovery|September 21, 2021
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase InhibitorsQing Li, Baishan Jiang, Jiaye Guo, et al.
Blood|December 14, 2023
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AMLWallace Bourgeois, Jevon A Cutler, Brandon J Aubrey, et al.
Nature Cancer|May 9, 2022
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemiaBrandon J Aubrey, Jevon A Cutler, Wallace Bourgeois, et al.
Nature Communications|June 30, 2022
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational statePeter G Miller, Murugappan Sathappa, Jamie A Moroco, et al.
Science Advances|February 6, 2021
Targeting oncoproteins with a positive selection assay for protein degradersVidyasagar Koduri, Leslie Duplaquet, Benjamin L Lampson, et al.
Pageof 16